Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13
about
Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammalsAndrogen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediatorRole of BRCA gene dysfunction in breast and ovarian cancer predisposition.BRCA1/2 mutation screening and LOH analysis of lung adenocarcinoma tissue in a multiple-cancer patient with a strong family history of breast cancerHomologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteinsUsing gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genesA population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.The breast cancer susceptibility gene, BRCA2: at the crossroads between DNA replication and recombination?Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer.Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families.The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.brca2 in zebrafish ovarian development, spermatogenesis, and tumorigenesisCommon mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.Li-Fraumeni syndrome--a molecular and clinical review.Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survivalA continuum model for tumour suppression.Secondary mutations of BRCA1/2 and drug resistanceGross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation.Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotypeAllelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer.Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene.Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells.Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersClinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significanceSecondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistanceFunctional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.Familial prostate cancer: the damage done and lessons learnt.Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivationThe carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry.BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells.Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infectionCharacterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks.Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics.Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
P2860
Q22010135-A176BC1A-107C-4249-9702-55D1738ABB38Q24290153-FF43311B-0AA9-4A73-BA3E-ADF0AF50D0B8Q24800677-29CEE5EA-908D-4FD2-B52C-3E0CEFC6D454Q24805707-19CD7289-6AF9-4E6C-8166-DC3D3156F8B6Q28085364-56EC06D5-3C47-4D11-9B8C-87EBE89EFEC1Q33680173-F8933B8B-EA2C-41DE-B153-F0A18CF84EA6Q33680801-6C4762D5-AC1C-4C07-94FA-34F4F044E785Q33867563-FD2CD83F-EF2A-4B8A-9EBD-0F00ED217BF7Q33901652-F80B58E7-E6FD-4F9A-90E4-3544D1EC6907Q33944203-C362E9D8-CA1A-445C-B62B-D044ED564595Q34168304-9D361C1B-5F78-4D35-9CA6-AAD99DEE0A6CQ34173446-BB4D7EDE-859E-477A-88DF-9090906D3AB0Q34288214-94710FE9-3DFA-4BFB-BFBD-301A38ADBCDFQ34320658-74866E3E-AC22-4DBD-8FD5-2A48AC51D7FBQ34335398-EDD4B17E-5DF0-459B-B1C6-F512FEEF0265Q34432117-1A1C2BE6-6FD9-47F6-B794-13C495B1FBF0Q34449010-5F29E6EA-7823-445F-AE60-9A08B573CC71Q34631552-5169A40F-2A21-4182-B12C-A94559516AECQ34983549-418E00CF-16E5-49FD-9AED-094D8B1709F8Q35195073-2561A80F-6FDB-4730-B290-F8D6B3125AD9Q35881865-2D520CA7-FA24-4140-9E57-D0C881346EB9Q36136605-7BE85FB1-B038-4EBE-887D-D671F2F184FDQ36617800-5709F688-6AD9-4C91-A1E4-8CA0C9EF4580Q36643587-3EEB5E95-B4FF-4330-B802-D88DCF10E911Q36687784-744AF6CD-D996-4BAA-9A26-83BC379564BEQ36958682-F104D92E-9898-4C11-9079-47FB53E7A671Q37117082-5DECC8CF-7C34-4CE4-B251-97D7C6D88565Q37172320-D9E89DAF-FB91-4D20-B719-D8CFC2AF1F7DQ37369575-7B8EA74E-1979-4F19-91B4-0C7304FBB5B1Q37410472-FA7A1652-AC7C-4DB4-B9C5-16A327E057CCQ37529633-09212FF0-6BF2-4EBA-B4AB-18C2C717A145Q37553869-48C70AA9-E379-4036-9AD0-25BED41950B9Q38165518-3B465859-8FA0-48FA-B5F1-A4DC61E53DE7Q39835877-90ADBF50-07A7-4DD1-8E53-F6F5FDFAB742Q40074639-5AD1D7BD-17AF-468F-8AD0-6C5E8E0B36C7Q41611182-F8DAAC97-2674-489B-B7CF-D2205158A85AQ41931140-E4E9FAA9-D715-4E42-9B6A-A4C74F705674Q42021790-8026F52B-7D03-4801-89CA-B24211FB0BBAQ43655387-151C6D3D-E1EC-4565-AB45-00F0C6885209Q46354502-0F477F27-6A1F-4ADC-878A-9A17E6D9AE6B
P2860
Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13
description
im November 1995 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 1995
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 1995
@uk
name
Different tumor types from BRC ...... omosome deletions on 13q12-q13
@en
Different tumor types from BRC ...... omosome deletions on 13q12-q13
@nl
type
label
Different tumor types from BRC ...... omosome deletions on 13q12-q13
@en
Different tumor types from BRC ...... omosome deletions on 13q12-q13
@nl
prefLabel
Different tumor types from BRC ...... omosome deletions on 13q12-q13
@en
Different tumor types from BRC ...... omosome deletions on 13q12-q13
@nl
P2093
P1433
P1476
Different tumor types from BRC ...... omosome deletions on 13q12-q13
@en
P2093
Barkardottir RB
Egilsson V
Gudmundsson J
Johannesdottir G
P304
P407
P577
1995-11-01T00:00:00Z